Compare · CANF vs CRVS
CANF vs CRVS
Side-by-side comparison of Can-Fite Biopharma Ltd (CANF) and Corvus Pharmaceuticals Inc. (CRVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CANF and CRVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- CRVS is the larger of the two at $1.30B, about 207.1x CANF ($6.3M).
- Over the past year, CANF is down 86.2% and CRVS is up 326.8% - CRVS leads by 413.0 points.
- CRVS has been more active in the news (8 items in the past 4 weeks vs 6 for CANF).
- CRVS has more recent analyst coverage (8 ratings vs 1 for CANF).
- Company
- Can-Fite Biopharma Ltd
- Corvus Pharmaceuticals Inc.
- Price
- $2.96-6.03%
- $15.45+1.78%
- Market cap
- $6.3M
- $1.30B
- 1M return
- -4.52%
- +7.22%
- 1Y return
- -86.17%
- +326.80%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- NASDAQ
- IPO
- 2016
- News (4w)
- 6
- 8
- Recent ratings
- 1
- 8
Can-Fite Biopharma Ltd
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, COVID-19 and erectile dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah-Tikva, Israel.
Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and activate various immune cells, as Phase III clinical trial of CPI-006 for COVID-19. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/II clinical trial for adenosine, an immune checkpoint. Its preclinical stage products include CPI-182, an antibody to block neutrophil function and migration, and myeloid derived suppressor cells; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
Latest CANF
- SEC Form 6-K filed by Can-Fite Biopharma Ltd
- Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
- SEC Form 6-K filed by Can-Fite Biopharma Ltd
- SEC Form 3 filed by new insider Tamir Ilan
- SEC Form 3 filed by new insider Regev Guy
- SEC Form EFFECT filed by Can-Fite Biopharma Ltd
- SEC Form 424B3 filed by Can-Fite Biopharma Ltd
- SEC Form EFFECT filed by Can-Fite Biopharma Ltd
- SEC Form EFFECT filed by Can-Fite Biopharma Ltd
- SEC Form F-3 filed by Can-Fite Biopharma Ltd
Latest CRVS
- SEC Form 4 filed by Director Chan Andrew C.
- SEC Form 3 filed by new insider Chan Andrew C.
- SEC Form DEF 14A filed by Corvus Pharmaceuticals Inc.
- SEC Form DEFA14A filed by Corvus Pharmaceuticals Inc.
- Corvus Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update
- Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors
- Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting
- Goldman initiated coverage on Corvus Pharmaceuticals with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Corvus Pharmaceuticals Inc.
- Corvus Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits